Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Not applicable Interventional Results available

Evaluation of Safety and Efficacy of the Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression

ClinicalTrials.gov ID: NCT05554471

Public ClinicalTrials.gov record NCT05554471. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Prospective, Randomized, Controlled, Open Label Trial to Evaluate the Safety and Efficacy of Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression in Patients Who Have Undergone Endovascular Procedures Utilizing up to 12F Procedural Sheaths

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

ReliaSeal is a clinical trial designed to evaluate safety and efficacy of use of MYNX CONTROL™ Venous Vascular Closure Device 6F-12F vs. manual compression to seal femoral access sites in patients who have undergone endovascular procedures utilizing up to 12F procedural sheaths in one or both limbs.

Study identification

NCT ID
NCT05554471
Recruitment status
Completed
Study type
Interventional
Phase
Not applicable
Lead sponsor
Cordis US Corp.
Industry
Enrollment
352 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 29, 2022
Primary completion
Jul 10, 2023
Completion
Jul 10, 2023
Last update posted
Apr 23, 2025

2022 – 2023

United States locations

U.S. sites
14
U.S. states
9
U.S. cities
13
Facility City State ZIP Site status
Arizona Cardiovascular Research Center Phoenix Arizona 85016
Colorado Heart and Vascular PC Lakewood Colorado 80228
Baptist Health Miami Cardiac and Vascular Institute Miami Florida 33176
Palm Vascular Centers Miami Beach Florida 33312
Tampa Cardiovascular Interventions and Research Tampa Florida 33614
Saint Luke's Hospital of Kansas City Kansas City Missouri 64111
NC Heart and Vascular Research Raleigh North Carolina 27607
Hightower Clinical Oklahoma City Oklahoma 73134
South Oklahoma Heart Research Oklahoma City Oklahoma 73135
OnSite Clinical Solutions Rock Hill South Carolina 28277
Erlanger Health System Chattanooga Tennessee 37403
Medical City Dallas Hospital Dallas Texas 75230
Rio Grande Regional Hospital McAllen Texas 78503
North Dallas Research Associates McKinney Texas 75069

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05554471, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 23, 2025 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05554471 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →